AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Alx Oncology Holdings (NASDAQ:ALXO)
1.38 USD
-0.200 12.658%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.58 |
|---|---|
| Change | -0.200 12.658% |
| 52 W H/L (in USD) | 2.660/0.404 |
| EBITDA (in USD) | -100.14M |
| PE Ratio | -- |
| Volume | 2945011 |
| Diluted Eps TTM | -1.84 |
| Total Assets (in USD) | 59.046M |
|---|---|
| Total Liabilities (in USD) | 33.065M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 16.373M |
| Market Cap (in USD) | 228.752 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.107M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
323 Allerton Avenue, South San Francisco, CA, United States, 94080
650 466 7125
Employees: 43
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Corey S. Goodman Ph.D. | Independent Exec. Chairman | 1951 |
| 2. | Dr. Jaume Pons Ph.D. | Founder, Pres, CEO & Director | 1967 |
| 3. | Mr. Peter S. Garcia M.B.A. | Chief Financial Officer | 1962 |
| 4. | Ms. Shelly Pinto | VP of Fin. & Chief Accounting Officer | 1977 |
| 5. | Dr. Sophia Randolph M.D., Ph.D. | Chief Medical Officer & Director | 1968 |
| 6. | Dr. Michael Chang Ph.D. | VP of Operations | NA |
| 7. | Dr. Chris Byrd J.D., Ph.D. | Gen. Counsel | NA |
| 8. | Ms. Jeanne Y. Jew | Chief Bus. Officer | 1964 |
| 9. | Dr. Athanasios Tsiatis M.D. | Sr. VP of Clinical Devel. | NA |
| 10. | Dr. Lin Yeong-Liang M.D., M.S. | Sr. VP of Drug Safety & Pharmacovigilance | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.370 0.842% | 44.03 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.001 0.003% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.710 0.602% | 452.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.250 0.041% | 615.18 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -101.695M | -134.85M | -160.805M | -123.418M | -83.484M |
| Minority Interest | - | - | - | - | - |
| Net Income | -101.695M | -134.85M | -160.805M | -123.482M | -83.463M |
| Selling General Administrative | 23.85M | 26.094M | 28.483M | 29.036M | 23.385M |
| Gross Profit | - | -0.872M | -0.836M | 0M | 0M |
| Reconciled Depreciation | 0.706M | 0.872M | 0.836M | 0.342M | 0.051M |
| Ebit | - | -133.121M | -159.24M | -127.778M | -83.555M |
| Ebitda | -100.846M | -132.249M | -158.404M | -127.436M | -83.471M |
| Depreciation And Amortization | - | 0.872M | 0.836M | 0.342M | 0.084M |
| Operating Income | -100.846M | -142.467M | -170.278M | -127.436M | -83.555M |
| Other Operating Expenses | 100.846M | 142.467M | 170.278M | 127.436M | 83.555M |
| Interest Expense | 1.602M | 1.729M | 1.565M | -4.36M | 0.013M |
| Tax Provision | 0M | 0M | 0M | 0.064M | -0.021M |
| Interest Income | 3.964M | 9.366M | 10.649M | 4.278M | - |
| Net Interest Income | 2.362M | 7.637M | 9.084M | 4.278M | -0.013M |
| Income Tax Expense | - | - | - | 0.064M | -0.021M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 100.846M | 142.467M | 170.278M | 127.436M | 83.555M |
| Cost Of Revenue | - | 0.872M | 0.836M | 0M | 0M |
| Total Other Income Expense Net | -0.849M | 7.617M | 9.473M | 4.018M | 0.071M |
| Net Income From Continuing Ops | -101.695M | -134.85M | -160.805M | -123.482M | -83.463M |
| Net Income Applicable To Common Shares | - | - | - | -123.482M | -83.463M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 59.046M | 147.775M | 242.553M | 306.489M | 380.183M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 5.639M | 5.703M | 4.923M | 4.762M | 3.352M |
| Total Liab | 33.065M | 34.157M | 52.841M | 43.025M | 17.134M |
| Total Stockholder Equity | 25.981M | 113.618M | 189.712M | -325.467M | -201.985M |
| Other Current Liab | 14.422M | 11.656M | 25.835M | 19.211M | 0.257M |
| Common Stock | 0.054M | 0.053M | 0.05M | 0.041M | 0.041M |
| Capital Stock | 0.054M | 0.053M | 0.05M | 0.041M | 0.041M |
| Retained Earnings | -722.817M | -621.122M | -486.272M | -325.467M | -201.985M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 9.008M | 12.267M |
| Cash | 16.373M | 17.567M | 22.406M | 282.906M | 363.667M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 24.553M | 18.5M | 36.001M | 28.325M | 15.295M |
| Current Deferred Revenue | - | - | - | - | 10.532M |
| Net Debt | -11.156M | -0.589M | -5.209M | -272.476M | -362.925M |
| Short Term Debt | 5.217M | 2.347M | 1.575M | 1.041M | 0.742M |
| Short Long Term Debt | 5.217M | 0.435M | - | - | - |
| Short Long Term Debt Total | 5.217M | 16.978M | 17.197M | 10.43M | 0.742M |
| Other Stockholder Equity | 748.716M | 734.412M | 675.678M | 0.804M | -0.041M |
| Property Plant Equipment | - | - | - | 3.889M | 0.897M |
| Total Current Assets | 50.727M | 134.352M | 188.659M | 270.969M | 367.019M |
| Long Term Investments | 3.494M | 3.524M | 35.411M | 16.699M | - |
| Short Term Investments | 28.417M | 110.19M | 160.33M | 217.385M | - |
| Net Receivables | 0.298M | 0.892M | 1M | - | - |
| Long Term Debt | 4.532M | 9.469M | 9.639M | 9.389M | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 4.914M | 4.497M | 8.591M | 8.073M | 3.764M |
| Accumulated Other Comprehensive Income | 0.028M | 0.275M | 0.256M | -0.845M | - |
| Non Currrent Assets Other | 3.625M | 0.267M | 7.576M | 9.008M | 9.692M |
| Non Current Assets Total | 8.319M | 13.423M | 53.894M | 35.52M | 13.164M |
| Capital Lease Obligations | - | - | 7.558M | 1.041M | 0.742M |
| Long Term Debt Total | - | - | - | 9.389M | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 82.798M | 86.256M | 44.657M | -233.989M | -4.923M |
| Total Cashflows From Investing Activities | 82.586M | 86.256M | 44.657M | -235.416M | -4.923M |
| Total Cash From Financing Activities | 0.362M | 30.817M | 59.291M | 9.86M | 2.472M |
| Net Income | -101.695M | -134.85M | -160.805M | -123.482M | -83.463M |
| Change In Cash | -1.194M | -4.839M | -26.416M | -314.779M | -70.552M |
| Begin Period Cash Flow | 17.633M | 22.472M | 48.888M | 363.667M | 434.219M |
| End Period Cash Flow | 16.439M | 17.633M | 22.472M | 48.888M | 363.667M |
| Total Cash From Operating Activities | -84.142M | -121.912M | -130.364M | -89.223M | -68.101M |
| Depreciation | 0.706M | 0.872M | 0.836M | 0.342M | 0.051M |
| Other Cashflows From Investing Activities | - | - | - | - | -4.257M |
| Dividends Paid | - | - | 59.679M | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0.024M | 0.351M | 0.523M | 0.336M | 0.202M |
| Other Cashflows From Financing Activities | 0.362M | 31.644M | 0.792M | 9.345M | 2.551M |
| Capital Expenditures | 0.212M | 0.447M | 1.274M | 1.427M | 4.923M |
| Change In Working Capital | 0.336M | -12.43M | 8.297M | 9.85M | -4.027M |
| Other Non Cash Items | 3.932M | -2.597M | -4.965M | 0.228M | 5.424M |
| Free Cash Flow | -84.354M | -122.359M | -131.638M | -90.65M | -73.024M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | HBM Healthcare Investments AG Ord | 5 months ago | 4769036 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 3642854 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 400719 |
| 4. | Fidelity Extended Market Index | 3 months ago | 189414 |
| 5. | Vanguard Instl Ttl Stck Mkt Idx Tr | 2 months ago | 120332 |
| 6. | Vanguard Health Care ETF | 2 months ago | 97881 |
| 7. | Fidelity Total Market Index | 3 months ago | 77665 |
| 8. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 2 months ago | 72511 |
| 9. | Extended Equity Market Fund E | 5 months ago | 64954 |
| 10. | Blackrock Extended Mkt Fund CF | 3 months ago | 64954 |
| 11. | Extended Equity Market Fund B | 5 months ago | 64954 |
| 12. | Vanguard Balanced Index Inv | 2 months ago | 63652 |
| 13. | Bridgeway Ultra-Small Company Market | 5 months ago | 61000 |
| 14. | Extended Equity Market Fund K | 2 months ago | 55306 |
| 15. | Fidelity Series Total Market Index | 3 months ago | 49321 |
| 16. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 44316 |
| 17. | NT Ext Equity Mkt Idx Fd - NL | 2 months ago | 35432 |
| 18. | Spartan Extended Market Index Pool F | 3 months ago | 34088 |
| 19. | Northern Trust Extended Eq Market Idx | 8 months ago | 28542 |
| 20. | Spartan Total Market Index Pool G | 3 months ago | 28354 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | venBio Partners LLC | 5 months ago | 9699925 |
| 2. | Redmile Group, LLC | 5 months ago | 3264718 |
| 3. | Millennium Management LLC | 5 months ago | 3204619 |
| 4. | Almitas Capital LLC | 5 months ago | 2536891 |
| 5. | Vanguard Group Inc | 5 months ago | 1630940 |
| 6. | Driehaus Capital Management LLC | 5 months ago | 1422882 |
| 7. | Two Sigma Advisers, LLC | 5 months ago | 710400 |
| 8. | Ameriprise Financial Inc | 8 months ago | 652897 |
| 9. | Two Sigma Investments LLC | 5 months ago | 640205 |
| 10. | Bank of America Corp | 8 months ago | 530828 |
| 11. | Bank of Montreal | 8 months ago | 474781 |
| 12. | BMO Capital Markets Corp. | 8 months ago | 474781 |
| 13. | BlackRock Inc | 8 months ago | 447692 |
| 14. | Renaissance Technologies Corp | 5 months ago | 423099 |
| 15. | Geode Capital Management, LLC | 5 months ago | 353696 |
| 16. | Jane Street Group LLC | 5 months ago | 185961 |
| 17. | UBS Group AG | 8 months ago | 172570 |
| 18. | Susquehanna International Group, LLP | 5 months ago | 151027 |
| 19. | JPMorgan Chase & Co | 8 months ago | 123798 |
| 20. | Seven Fleet Capital Management LP | 5 months ago | 117817 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...